Clinical Trial

Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma

Study acronym: BCB-OVAIRE
Recruiting
View on ClinicalTrials.gov →
Summary
Cancer of the ovary and/or peritoneum and/or fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies. The main objective of this study is to implement prognostic model of overall survival on patients included prospectively as part of the initial treatment of advanced ovarian and/or peritoneum, and/or fallopian tubes carcinoma (this cohort corresponds to the "Turquoise" care pathway of the Oscar Lambret Center) regardless of the treatment carried out,, integrating both patient's and tumor's characteristics. A clinical and biological database is implemented for this purpose. 371 patients will be recruited over a 5-year period at the Oscar Lambret Center. The active participation of each patient will be 2 years (from the date of pre-registration until the end of study participation, defined by the date of the last intervention specific to the research), then the data from standard care and survival data will be collected until the last follow-up of the last patient, 2 years after the last pre-registration.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-09; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2025-06-27
Trial Details
NCT Number NCT06969833
Lead Sponsor Centre Oscar Lambret
Conditions Cancer of the Ovary, Cancer of the Fallopian Tube, Peritoneal Cancer
Enrollment 371 participants
Start Date 2025-06-27
Primary Completion 2032-06-27 (estimated)
Study Completion 2032-06-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-30